UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000041815
Receipt number R000047739
Scientific Title Assessment of DNA methylation on MGMT gene in patients with glioma (a prospective study)
Date of disclosure of the study information 2020/12/01
Last modified on 2023/03/20 09:48:48

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Assessment of DNA methylation on MGMT gene in patients with glioma (prospective study)

Acronym

DNA methylation on MGMT gene in glioma

Scientific Title

Assessment of DNA methylation on MGMT gene in patients with glioma (a prospective study)

Scientific Title:Acronym

DNA methylation on MGMT gene in glioma

Region

Japan


Condition

Condition

Glioma

Classification by specialty

Neurosurgery Adult Child

Classification by malignancy

Malignancy

Genomic information

YES


Objectives

Narrative objectives1

To clarify whether results of MGMT methylation on MGMT gene from PCR test in our institute can predict therapeutic response of anti-cancer agents in patients with glioma

Basic objectives2

Others

Basic objectives -Others

Assessment of accuracy in results from PCR test in our Institute

Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

Relationship between MGMT methylation and overall survival period

Key secondary outcomes

Relationship between MGMT methylation and progression-free survival period


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Patients who will undergo surgical tumor removal as well as will receive chemotherapy for glioma

Key exclusion criteria

Patients who have double cancers

Target sample size

50


Research contact person

Name of lead principal investigator

1st name Takaaki
Middle name
Last name Beppu

Organization

Iwate Medical University

Division name

Neurosurgery

Zip code

028-3695

Address

2-1-1 Idaidori, Yahaba, Shiwa, Iwate Prefecture

TEL

019-613-7111

Email

tbeppu@iwate-med.ac.jp


Public contact

Name of contact person

1st name Takaaki
Middle name
Last name Beppu

Organization

Iwate Medical University

Division name

Neurosurgery

Zip code

028-3695

Address

2-1-1 Idaidori, Yahaba, Shiwa, Iwate Prefecture

TEL

019-613-7111

Homepage URL


Email

tbeppu@iwate-med.ac.jp


Sponsor or person

Institute

Department of Neurosurgery, Iwate Medical University

Institute

Department

Personal name



Funding Source

Organization

Grant-in-Aid for JSPS KAKENHI from the Ministry of Education,Culture, Sports, Science and Technology of Japan

Organization

Division

Category of Funding Organization

Japanese Governmental office

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

IRB of Iwate Medical University

Address

1-1-1 Idaidori, Yahaba, Shiwa, Iwate Prefecture

Tel

019-651-5111

Email

kenkyu-rinri@j.iwate-med.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

岩手医科大学病院(岩手県)


Other administrative information

Date of disclosure of the study information

2020 Year 12 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2020 Year 12 Month 02 Day

Date of IRB

2000 Year 11 Month 05 Day

Anticipated trial start date

2020 Year 12 Month 02 Day

Last follow-up date

2026 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

Using tumor tissue obtained from surgical removal for patients with glioma, we will assess MGMT gene status is either methylation or unmethylation. After standard treatment, patients are assigned to 2 groups, methylated MGMT and unmethylated MGMT. We will compare therapeutic response, progression-free survival time, and overall survival time between 2 groups.


Management information

Registered date

2020 Year 09 Month 16 Day

Last modified on

2023 Year 03 Month 20 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000047739


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name